• Insilico’s Alex Zhavoronkov Highlights Generative AI's Impact on Drug Discovery and Aging Research

    Apr 17 | Bio-IT World | At the Bio-IT World Conference & Expo earlier this month, Alex Zhavoronkov, CEO and founder of Insilico Medicine, shared the company's progress in leveraging generative AI to accelerate drug discovery, particularly focusing on aging research. Celebrating the company's 11th year, Zhavoronkov emphasized his singular mission: helping people live longer, healthier lives. More
  • AI Continues to Make Strides on Therapeutics and Research Progress

    Apr 16 | Bio-IT World | During the final plenary keynote of this year’s Bio-IT World Conference & Expo, we heard from Tris Dyson, Challenge Works, and Jeffrey Rothstein, Johns Hopkins University; Robert Green, Harvard Medical School; and Justin Scheer, Johnson & Johnson Innovative Medicine. They all gave presentations that highlighted artificial intelligence (AI) and machine learning’s (ML) ever-growing roles in research and healthcare, as well as the impact they have on the future of patient treatment, drug development, and more. More
  • Derek Lowe on AI in Drug Discovery: Between Hype and Hope

    Apr 15 | Bio-IT World | At last week’s Venture, Innovation, and Partnering Summit at the Bio-IT World Conference & Expo, Derek Lowe, Director, Chemical Biology & Therapeutics at Novartis BioMedical Research, and John Keilty, venture partner at Third Rock Ventures, sat down for a candid conversation on the pharmaceutical industry and the current state of artificial intelligence and machine learning (AI/ML) in drug discovery. More
  • Large Language Model Predicts, as Well as Explains, Molecular Properties

    Apr 10 | Bio-IT World | Scientists use prior knowledge to solve new problems, and a novel artificial intelligence (AI) system known as LLM4SD (Large Language Model 4 Scientific Discovery) can likewise synthesize knowledge from existing literature. But the method “goes beyond simply repeating information” by interpreting it and coming up with new hypotheses. More
  • AI Struggles and Opportunities in Life Sciences and Healthcare

    Apr 09 | Bio-IT World | At the opening plenary panel at last week’s Bio-IT World Conference & Expo, speakers from pharma, healthcare, and biotech took on the future of AI for pharma and healthcare. Abbie Celniker, Partner, Third Rock Ventures, moderated the conversation which included viewpoints from Per Greisen, President, BioMap; Sofia Guerra, Vice President, Bessemer Venture Partners; Subha Madhavan, Vice President and Head, AI/ML, Quantitative and Digital Sciences, Pfizer; and Sonya Makhni, MD, Medical Director, Mayo Clinic Platform. More
  • Researchers Transform Gut Bacteria into ‘Little Pharmacists’

    Apr 08 | Bio-IT World| Oral drugs are considered an ideal delivery method for medications because of their noninvasive nature, but they face the challenge of passing through the acidic environment of the upper gastrointestinal (GI) tract. Specifically, the stomach acts as a barrier to anything biological, including oral drugs with biologic content. To overcome this obstacle, a team of researchers at Virginia Tech engineered microbes called bacteriophages, or phages, to infect and reprogram gut bacterial cells to produce and release a sustained flow of a protein-based drug. More
  • Bio-IT Community Honors New Products from Boulder BioComputing, Dantech Corp, The Hyve, Velsera

    Apr 04 | Bio-IT World | Yesterday in Boston the Bio-IT World community at the Bio-IT World Conference & Expo honored four new products in the annual Bio-IT World Best of Show competition. New products from Boulder BioComputing, Dantech Corp, The Hyve, and Velsera took top honors. More
  • Evaluating the Benefits and Risks of Weight Loss Drugs

    Apr 03 | Bio-IT World| Weight loss medications are in “skyrocketing” utilization. Yet there have been no comprehensive investigations or studies on the effectiveness and risks of glucagon-like peptide-1 receptor agents (GLP-1RA). Researchers at the WashU Medicine collaborated with the Veterans Affairs (VA) St. Louis Health Care System to examine and evaluate more than two million people with diabetes taking popular weight loss drugs such as Ozempic. More
  • Large Genetic Study Further Untangles the Height-Health Connection

    Apr 02 | Bio-IT World| In the largest phenome wide association study across diverse population groups, an international team of researchers have identified 254 statistically significant associations between genetically explained height and various diseases. Genetically predicted height was linked with decreased risk of 90 diseases and increased risk of 164 others, most notably atrial fibrillation, and a series of conditions involving mental health and the endocrine system that have not been previously described. More
  • Bio-IT World Best of Show Finalists Named

    Mar 28 | Bio-IT World| Finalists have been named for the 2025 Bio-IT World Best of Show Awards program. More than 20 new products will be on display next week at the Bio-IT World Conference & Expo. New products will be on display from Artificial, Boulder BioComputing, Copyright Clearance Center, Chemspace, Dantech Corporation, Discngine, expert.ai, Genomenon, Globus, GRAU DATA, iuvo, Komprise, Orchestra Bio, Quantum Corporation, QuartzBio, Sinequa, Tech Mahindra, TetraScience, The Hyve, and Velsera. More
View more articles
Bio IT World Lead Gen

 
Industry-spotlight

Riffyn’s pioneering cloud system, Riffyn Nexus, delivers 2X faster development cycles and 4X productivity gains to the world’s most advanced scientific R&D organizations. Its process-centric experiment design, data capture, and data analytics overcome the limitations of ELN and LIMS systems. Its adaptive data integration engine delivers results that are always ready for machine learning.
Read more here!

Industry-spotlight
Trends from the Trenches

Bio-IT World’s Trends from the Trenches podcast delivers your insider’s look at the science, technology, and executive trends driving the life sciences through conversations with industry leaders. BioTeam co-founder Stan Gloss brings years of industry experience in science, data, and technology to conversations exploring what is driving data and discovery, and what’s coming next.
Listen today!